유타의 흑색종 임상 시험
흑색종 관련 연구 26개가 유타 내 여러 지역에서 참여자를 모집하고 있습니다.
유타의 도시
공식 연구 텍스트(영어)
A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)
- University of Utah Huntsman Cancer Institute, Salt Lake City
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06246916BiCaZO: A Study Combining Two Immunotherapies (Cabozantinib and Nivolumab) to Treat Patients With Advanced Melanoma or Squamous Cell Head and Neck Cancer, an immunoMATCH Pilot Study
- Huntsman Cancer Institute/University of Utah, Salt Lake City
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT05136196A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
- Primary Children's Hospital, Salt Lake City
피험자 모집 중2상
25세 이하 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT07621614Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
- Intermountain Health, Salt Lake City
피험자 모집 중3상
18세 ~ 70세 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT05727904Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- University of Utah - Huntsman Cancer Institute, Salt Lake City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT05267626A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases
- Huntsman Cancer Institute/University of Utah, Salt Lake City
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 15. 업데이트됨 · NCT04511013ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- Utah Cancer Specialists, Salt Lake City
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 9. 14. 업데이트됨 · NCT05059444Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
- START Mountain Region, West Valley City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT07287917A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors
- START Mountain Region, West Valley City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 9. 2. 업데이트됨 · NCT07070232Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
- Huntsman Cancer Institute/University of Utah, Salt Lake City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 31. 업데이트됨 · NCT05896839Project: Every Child for Younger Patients With Cancer
- Primary Children's Hospital, Salt Lake City
피험자 모집 중관찰 연구
25세 이하 · 모든 성별 · 2026. 8. 25. 업데이트됨 · NCT02402244A Study of MGC026 in Participants With Advanced Solid Tumors
- START Mountain Region, West Valley City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 11. 업데이트됨 · NCT06242470Rural Adult and Youth Sun Protection Study
- University of Utah, Salt Lake City
피험자 모집 중건강한 지원자 환영
3세 ~ 7세 · 모든 성별 · 2026. 8. 10. 업데이트됨 · NCT06439979A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
- START Mountain Region, West Valley City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 10. 업데이트됨 · NCT06880549A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
- Huntsman Cancer Institute, University of Utah, Salt Lake City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 8. 5. 업데이트됨 · NCT06330064A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
- START Mountain Region, West Valley City
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 8. 3. 업데이트됨 · NCT06270706Sun Exposure and Activities After Skin Cancer: Optimization of mHealth Interventions
- Huntsman Cancer Institute at The University of Utah, Salt Lake City
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 7. 10. 업데이트됨 · NCT07556380Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma
- Huntsman Cancer Institute, Salt Lake City
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 7. 2. 업데이트됨 · NCT06365619Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- Huntsman Cancer Institute, Salt Lake City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 5. 15. 업데이트됨 · NCT05379985Comparative Effectiveness Trial of Two Supportive Cancer Care Delivery Models for Adults With Cancer
- George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City
피험자 모집 중
18세 이상 · 모든 성별 · 2026. 4. 30. 업데이트됨 · NCT05297734Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)
- University of Utah Huntsman Cancer Institute, Salt Lake City
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 2. 25. 업데이트됨 · NCT05549297Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients
- Huntsman Cancer Institute, University of Utah 2000 Circle of Hope, Salt Lake City, UT
피험자 모집 중3상
18세 이상 · 모든 성별 · 2025. 12. 17. 업데이트됨 · NCT03567889Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
- Huntsman Cancer Institute, Salt Lake City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 12. 3. 업데이트됨 · NCT06194929Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
- Huntsman Cancer Institute - University of Utah, Salt Lake City
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2025. 10. 29. 업데이트됨 · NCT06249048SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
- Massive Bio SYNERGY-AI site, Salt Lake City
피험자 모집 중관찰 연구
전 연령 · 모든 성별 · 2025. 10. 28. 업데이트됨 · NCT03452774Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma
- Intermountain Medical Center, Murray
- Huntsman Cancer Institute (The University of Utah), Salt Lake City
피험자 모집 중
18세 이상 · 모든 성별 · 2024. 11. 27. 업데이트됨 · NCT03860883ClinicalTrials.gov 출처, 2026. 9. 30. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.